Cannabis in the United States

Cannabis is subject to a complex legal regime in the United States, with conflicting federal and state policies governing medical, industrial, recreational, and other uses. As of April 2026, the use, sale, and possession of cannabis containing over 0 % THC by dry weight is illegal under federal law except for medical use in some states. As a Schedule I drug under the federal Controlled Substances Act (CSA) of 1970, cannabis was historically considered to have "no accepted medical use" and a high potential for abuse and physical or psychological dependence. As a result, cannabis use was illegal for any reason, with the exception of FDA-approved research programs. However, individual states have enacted legislation permitting exemptions for various uses, including medical, industrial, and recreational uses. Cannabis for industrial uses (hemp) was made illegal to grow without a permit under the CSA because of its relation to cannabis as a drug, and any imported products must adhere to a zero tolerance policy. The Agricultural Act of 2014 allows for universities and state-level departments of agriculture to cultivate cannabis for research into its industrial potential. In December 2018, hemp was permitted to be grown in the U . under federal law after the Hemp Farming Act was included in the passed 2018 Farm Bill. As a psychoactive drug, cannabis continues to find extensive favor among recreational and medical users in the U . As of 2023, twenty-four states, three U . territories, and the District of Columbia have legalized recreational use of cannabis. Thirty-eight states, four U . territories, and D . have legalized medical use of the drug. Multiple efforts to reschedule cannabis under the CSA have failed, and the U . Supreme Court has ruled in United States v. Oakland Cannabis Buyers' Cooperative (2001) and Gonzales v. Raich (2005) that the federal government has a right to regulate and criminalize cannabis, whether medical or recreational. As a result, cannabis dispensaries are licensed by each state; these businesses sell cannabis products that have not been approved by the U . Food and Drug Administration, nor are they legally registered with the federal government to sell controlled substances. Although cannabis has not been approved, the FDA recognizes the potential benefits and has approved two drugs that contain components of marijuana. The ability of states to implement cannabis legalization policies was weakened after U . Attorney General Jeff Sessions rescinded the Obama administration's Cole Memorandum on January 4, 2018, and issued a new memo instructing U . attorneys to enforce federal law related to marijuana. The Cole memo, issued by former Deputy Attorney General James Cole in 2013, urged federal prosecutors to refrain from targeting state-legal marijuana operations. Regarding the medical use of cannabis, the Rohrabacher–Farr amendment still remains in effect to protect state-legal medical cannabis activities from enforcement of federal law. In 2024, the Joe Biden administration began the process of reclassifying marijuana to a Schedule III drug, easing restrictions. On December 18, 2025, President Donald Trump signed an executive order instructing the Attorney General to expedite the process of reclassify cannabis from a Schedule I drug (the most restrictive classification) to Schedule III. On April 23rd 2026, the Justice Department issued an order to place FDA-approved products containing cannabis and products regulated by a state medical marijuana license in Schedule III.